Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-Clinical Diagnostics Licenses Intrinsic Bioprobes' Markers

NEW YORK (GenomeWeb News) – Intrinsic Bioprobes, a private clinical diagnostics developer, said today that it has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, a Johnson & Johnson company.

The blood-circulating proteins covered under the license, which were discovered using Intrinsic's mass spectrometry-based technology, have been linked with the presence of pre-diabetes and type 2 diabetes, the Tempe, Ariz.-based company said.

"The biomarkers were extensively tested and shown to have statistically significant clinical sensitivities in differentiating subjects with pre- and type-2 diabetes from healthy controls," explained Urban Kiernan, director of biomarker discovery at Intrinsic Probes.

The research leading to the discovery of these markers was funded with a five-year, $2 million grant from the National Institutes of Health, and the studies were conducted in collaboration with Yale University.

Intrinsic Bioprobes' technologies include the Mass Spectrometric Immunoassay, used for isolating proteins from complex matrices, and Bioreactive Mass Spectrometer Probes, which are used in protein characterization.

Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.